ADC Therapeutics Sàrl

Launched in 2012, ADC Therapeutics Sarl (ADCT) is focused on the development of proprietary Antibody Drug Conjugates (ADC) for the treatment of cancer.

The Companys ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD) based warheads developed by ADCTs partner Spirogen Limited.

The antibodies bind to specific receptors (antigens) on the surface of the target cancer cell. Once internalized into the target cell, the PBD-based warhead is released, killing the cell directly. This minimizes the impact on normal, healthy tissues and significantly reduces the side effects associated with chemotherapy treatments. In addition, PBD-based chemistry does not distort th